(FM) Hematología
Departamento académico
University of Sydney
Sídney, AustraliaPublicaciones en colaboración con investigadores/as de University of Sydney (4)
2024
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387
2018
-
Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: Influence of chemotherapy on efficacy and safety
Journal of Clinical Oncology, Vol. 36, Núm. 23, pp. 2395-2404
-
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 11, pp. 1530-1542
2017
-
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
The Lancet, Vol. 390, Núm. 10094, pp. 555-566